Evidence map›Paper›PMID 36474670›Full record

ArticleJournal of hepatocellular carcinoma2022

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.

Jin-Tao Huang, Bin-Yan Zhong, Nan Jiang, Wan-Ci Li, Shuai Zhang, Yu Yin, Jun Yang, Jian Shen, Wan-Sheng Wang, Xiao-Li Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jin-Tao Huang *Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Bin-Yan Zhong *Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.ORCID 0000-0001-9716-1211
Nan Jiang *Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Wan-Ci LiDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Shuai ZhangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Yu YinDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Jun YangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Jian ShenDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Wan-Sheng WangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Xiao-Li ZhuDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate the effectiveness and safety of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) (TACE+IT) versus ICIs plus TKIs (IT) for advanced hepatocellular carcinoma (HCC). Materials and Methods: Data of consecutive advanced HCC patients receiving TACE+IT or IT between January 2019 and December 2021 were included and were retrospectively analyzed. Propensity score matching (PSM) was performed to reduce bias due to confounding variables. The primary outcome of the study was overall survival (OS). The secondary outcomes were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs), respectively. Results: Sixty-four patients were enrolled in the study, among which 24 and 40 received TACE+IT and IT, respectively. The PSM cohort included 24 patients receiving TACE+IT (TACE+IT group) and 24 patients receiving IT (IT group) alone. During a median follow-up of 23 months, patients in TACE+IT group had significantly longer OS (median, 17.3 vs 11.8 months, Conclusion: TACE combined with ICIs plus TKIs significantly improved OS, ORR, and DCR and showed a relatively longer PFS trend over ICIs combined with TKIs for advanced HCC.

Indexed as

hepatocellular carcinomaimmune checkpoint inhibitorstransarterial chemoembolizationtyrosine kinase inhibitors

Identifiers

PMID36474670
PMCPMC9719708
OpenAlexW4310342535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.